Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

On-the-run prisoner discovered hiding in loft after escaping with fake bail letter - ‘Americans are going to feel it’: Bessent forecasts price shift Carney says back-to-office plan for federal civil ...